|
M.B. Antsiferov (1), G. Schernthaner (2)
CURRENT APPROACHES TO THERAPY OF TYPE 2 DIABETES MELLITUS IN THE ERA OF NEW DATA ON CARDIOVASCULAR SAFETY
|
8-16 |
|
A.V. Pashentseva, A.F. Verbovoy
OSTEOPOROSIS IN MEN
|
17-22 |
|
L.V. Egshatyan (1), A.M. Mkrtumyan (1), L.A. Zvenigorodskaya (2)
METABOLIC SYNDROME AND INTESTINAL MICROBIOTA
|
23-28 |
|
A.F. Verbovoy, L.A. Sharonova
DIABETES MELLITUS AND CORONARY ARTERY DISEASE: FEATURES OF CLINICAL MANIFESTATION AND TREATMENT.
|
29-35 |
|
M.B. Antsiferov
CLINICAL CHARACTERISTICS AND PRACTICAL ASPECTS OF THE USE OF NEW BASAL INSULIN GLARGINE 300 U/ ML TOUJEO SOLOSTAR®
|
36-40 |
|
A.F. Verbovoy, R.I. Sagirova, Yu. A. Dolgikh, L.A. Sharonova
SOME ASPECTS OF PATHOGENESIS OF INSULIN RESISTANCE
|
41-45 |
|
A.F. Verbovoy, R.I. Sagirova, Yu. A. Dolgikh
OBESITY AND BRONCHIAL ASTHMA
|
46-49 |
|
M.B. Antsiferov (1), V.V. Fadeev (2), T.B. Morgunova (2)
MODERN APPROACHES TO THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
50-55 |
|
A.M. Mkrtumyan (1), S.V. Podachina (1), M.I. Sviridova (2)
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON CARDIOVASCULAR RISK MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
56-61 |
|
M.B. Antsiferov (1), T.M. Alekseeva (1), V.S. Pronin (2)
MOSCOW REGISTRY OF PATIENTS WITH ACROMEGALY: LONG-TERM RESULTS OF OBSERVATIONS
|
62-66 |
|
E.V. Kovrigina (1, 2), V.L. Tyulganova (1, 2)
ADVANTAGES OF THE USE OF INSULIN ASPART IN INSULIN PUMP THERAPY
|
67-75 |
|
M.B. Antsiferov
FEATURES OF USE OF DAPAGLIFLOZIN IN THETREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
76-79 |
Русский
